India, May 6 -- Wednesday, Nuvation Bio Inc. (NUVB) announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application with updated data for IBTROZI for the treatment of advanced ROS1-positive non-small cell lung cancer, with a target action date of January 4, 2027.
The submission includes an additional 10 months of data from the pivotal TRUST-I and TRUST-II studies as of an August 2025 data cutoff, further validating the overall clinical profile with long-term follow-up.
These findings revealed that IBTROZI demonstrated a median duration of response of 49.7 months and a median progression-free survival of 49.6 months in TKI-naive patients in TRUST-I. However, the median duration of response had not yet ...